english.prescrire.org > Spotlight > 100 most recent > In the May issue of Prescrire International: Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the May issue of Prescrire International: Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer

FREE DOWNLOAD A solution for subcutaneous injection containing a fixed-dose combination of these two anti-HER2 monoclonal antibodies has been authorised in the EU. How do Prescrire's editors rate this combination in its new form?
Full text available for free download.

Prescrire's rating

  OFFERS AN ADVANTAGE  Subcutaneous injection is quicker than intravenous administration. In Europe, this drug is restricted to hospital use. The harm-benefit balance of pertuzumab + trastuzumab is only favourable in women with inoperable breast cancer. 


©Prescrire 1 May 2022

Source: "Pertuzumab + trastuzumab (Phesgo°) by subcutaneous injection, in certain types of breast cancer" Prescrire International 2022; 31 (237): 123. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Prescrire's rating:
 
 Prescrire's rating
 OFFERS AN ADVANTAGE 


See also:

"Prescrire's ratings for new
drugs and new indications"
(February 2022)
Free

"Pertuzumab and metastatic
breast cancer. Longer
survival confirmed, but
cardiac risks to be monitored"
Prescrire Int 2017;
26 (184): 178-179.
Pdf, subscribers only

Read more:

All the subjects in
Prescrire's Spotlight
Free >